The Effects of Vitamin D3 and Melatonin Combination on Pentylenetetrazole- induced Seizures in Mice
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: Epileptic seizures are associated with the overproduction of free radicals in the brain leading to neuronal cell death. Therefore, reduction of oxidative stress may inhibit seizure- induced neuronal cell damage. The current study evaluated the effects of Vit D3 and melatonin and their combination on pentylenetetrazol (PTZ)-induced tonic-clonic seizures in mice.
METHODS: Animals were divided into six groups. Group I was administered with normal saline (0.5 ml, intraperitoneally (i.p.)) on the 15th day of the experiment. Group II was injected with PTZ (60 mg/kg dissolved in 0.5 ml normal saline, i.p) on the 15th day. Groups III-IV were treated with diazepam (4 mg/kg/day), Vit D3 (6000 IU/kg/day), melatonin (20 mg/kg/day), and Vit D3 (6000 IU/kg/day)/melatonin (20 mg/kg/day), respectively, and were then injected with PTZ (60 mg/kg) on the 15th day of the experiment. Immediately after the injection of PTZ on the 15th day, mice were observed for a 30-min period to measure seizure latency and duration. For determination of oxidative stress markers, malondialdehyde (MDA) level and superoxide dismutase (SOD) activity were measured in mouse brains.
RESULTS: Treatment with Vit D3, melatonin, and Vit D3/melatonin significantly increased seizure latency and decreased seizure duration. The brain level of MDA was lower, and SOD activity was greater than in the PTZ group. Mice treated with Vit D3/melatonin had lower seizure duration than other treated groups.
CONCLUSIONS: The combination of Vit D3 and melatonin may reduce seizure frequency in epileptic patients; this effect may result from various mechanisms, including inhibition of oxidative stress.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Central nervous system agents in medicinal chemistry - 22(2022), 2 vom: 01., Seite 118-124 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hosseinzadeh, Azam [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.09.2022 Date Revised 26.09.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1871524922666220429121253 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340364548 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340364548 | ||
| 003 | DE-627 | ||
| 005 | 20231226005022.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1871524922666220429121253 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1134.xml |
| 035 | |a (DE-627)NLM340364548 | ||
| 035 | |a (NLM)35507790 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hosseinzadeh, Azam |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Effects of Vitamin D3 and Melatonin Combination on Pentylenetetrazole- induced Seizures in Mice |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.09.2022 | ||
| 500 | |a Date Revised 26.09.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: Epileptic seizures are associated with the overproduction of free radicals in the brain leading to neuronal cell death. Therefore, reduction of oxidative stress may inhibit seizure- induced neuronal cell damage. The current study evaluated the effects of Vit D3 and melatonin and their combination on pentylenetetrazol (PTZ)-induced tonic-clonic seizures in mice | ||
| 520 | |a METHODS: Animals were divided into six groups. Group I was administered with normal saline (0.5 ml, intraperitoneally (i.p.)) on the 15th day of the experiment. Group II was injected with PTZ (60 mg/kg dissolved in 0.5 ml normal saline, i.p) on the 15th day. Groups III-IV were treated with diazepam (4 mg/kg/day), Vit D3 (6000 IU/kg/day), melatonin (20 mg/kg/day), and Vit D3 (6000 IU/kg/day)/melatonin (20 mg/kg/day), respectively, and were then injected with PTZ (60 mg/kg) on the 15th day of the experiment. Immediately after the injection of PTZ on the 15th day, mice were observed for a 30-min period to measure seizure latency and duration. For determination of oxidative stress markers, malondialdehyde (MDA) level and superoxide dismutase (SOD) activity were measured in mouse brains | ||
| 520 | |a RESULTS: Treatment with Vit D3, melatonin, and Vit D3/melatonin significantly increased seizure latency and decreased seizure duration. The brain level of MDA was lower, and SOD activity was greater than in the PTZ group. Mice treated with Vit D3/melatonin had lower seizure duration than other treated groups | ||
| 520 | |a CONCLUSIONS: The combination of Vit D3 and melatonin may reduce seizure frequency in epileptic patients; this effect may result from various mechanisms, including inhibition of oxidative stress | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Seizures | |
| 650 | 4 | |a epilepsy | |
| 650 | 4 | |a melatonin | |
| 650 | 4 | |a oxidative stress | |
| 650 | 4 | |a pharmacology | |
| 650 | 4 | |a vitamin D3 | |
| 650 | 7 | |a Anticonvulsants |2 NLM | |
| 650 | 7 | |a Saline Solution |2 NLM | |
| 650 | 7 | |a Cholecalciferol |2 NLM | |
| 650 | 7 | |a 1C6V77QF41 |2 NLM | |
| 650 | 7 | |a Superoxide Dismutase |2 NLM | |
| 650 | 7 | |a EC 1.15.1.1 |2 NLM | |
| 650 | 7 | |a Melatonin |2 NLM | |
| 650 | 7 | |a JL5DK93RCL |2 NLM | |
| 650 | 7 | |a Pentylenetetrazole |2 NLM | |
| 650 | 7 | |a WM5Z385K7T |2 NLM | |
| 700 | 1 | |a Dehdashtian, Ehsan |e verfasserin |4 aut | |
| 700 | 1 | |a Jafari-Sabet, Majid |e verfasserin |4 aut | |
| 700 | 1 | |a Mehrzadi, Saeed |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Central nervous system agents in medicinal chemistry |d 2008 |g 22(2022), 2 vom: 01., Seite 118-124 |w (DE-627)NLM185149960 |x 1875-6166 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:2 |g day:01 |g pages:118-124 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871524922666220429121253 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 2 |b 01 |h 118-124 | ||